Barclays PLC Cure Vac N.V. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Cure Vac N.V. stock. As of the latest transaction made, Barclays PLC holds 22,946 shares of CVAC stock, worth $65,855. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,946

Previous 22,946 -0.0%

Holding current value

$65,855

Previous $67,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$2.74 - $3.79 $62,872 - $86,965	22,946 New	22,946 $67,000
Q1 2024 May 15, 2024	SELL	$2.94 - $4.34 $237,928 - $351,227	-80,928 Reduced 86.82%	12,289 $37,000
Q4 2023 Feb 15, 2024	SELL	$3.96 - $6.41 $17,538 - $28,389	-4,429 Reduced 4.54%	93,217 $393,000
Q3 2023 Nov 07, 2023	SELL	$6.5 - $10.77 $125,424 - $207,817	-19,296 Reduced 16.5%	97,646 $666,000
Q2 2023 Aug 03, 2023	BUY	$6.69 - $12.25 $112,271 - $205,579	16,782 Added 16.76%	116,942 $1.22 Million
Q1 2023 May 04, 2023	SELL	$6.38 - $12.5 $160,074 - $313,625	-25,090 Reduced 20.03%	100,160 $698,000
Q4 2022 Feb 13, 2023	BUY	$5.75 - $8.5 $311,621 - $460,657	54,195 Added 76.27%	125,250 $755,000
Q3 2022 Nov 03, 2022	SELL	$7.48 - $15.24 $246,473 - $502,173	-32,951 Reduced 31.68%	71,055 $561,000
Q2 2022 Aug 12, 2022	BUY	$13.18 - $19.41 $292,081 - $430,145	22,161 Added 27.08%	104,006 $1.42 Million
Q1 2022 May 16, 2022	BUY	$14.73 - $35.25 $1.21 Million - $2.89 Million	81,845 New	81,845 $1.61 Million

Others Institutions Holding CVAC

# of Institutions

Shares Held

12.3M

Call Options Held

164K

Put Options Held

117K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account